Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Richard

Showing results (711-720 of 781) with videos related to

Pageof 79
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 18, 2006
Low molecular weight indole fragments as IMPDH inhibitorsRebekah E Beevers, George M Buckley, Natasha Davies, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 2006
Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationshipsRebekah E Beevers, George M Buckley, Natasha Davies, et al.
Trials|February 14, 2026
Optimising Prescription of Treatment In older patients with Mild hypertension at Increased risk of Serious adverse Events (OPTIMISE2): protocol for a primary care based, open-label, randomised controlled non-inferiority trialMelanie Carr, Nicola Kenealy, Ly-Mee Yu, et al.
Journal of Hypertension|May 16, 2025
Developing prediction models for electrolyte abnormalities in patients indicated for antihypertensive therapy: evidence-based treatment and monitoring recommendationsAriel Wang, Constantinos Koshiaris, Lucinda Archer, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Quinazolinethiones and quinazolinediones, novel inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-activity relationshipsGeorge M Buckley, Natasha Davies, Hazel J Dyke, et al.
The Lancet. Healthy Longevity|August 2, 2024
Effect of antihypertensive deprescribing on hospitalisation and mortality: long-term follow-up of the OPTiMISE randomised controlled trialJames P Sheppard, Eleanor Temple, Ariel Wang, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 5, 2010
Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registryCyril William Helm, Scott D Richard, Jianmin Pan, et al.
BMJ Open|October 6, 2018
OPtimising Treatment for MIld Systolic hypertension in the Elderly (OPTiMISE): protocol for a randomised controlled non-inferiority trialJames P Sheppard, Jenni Burt, Mark Lown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)Annie M Young, Andrea Marshall, Jenny Thirlwall, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 11, 2025
Assessing the association between COVID-19 vaccination and thrombotic thrombocytopenia syndrome (ATTEST Study): Analyses of English data, 2020-2022José M Ordóñez-Mena, Xinchun Gu, Mark Joy, et al.
Pageof 79

Showing results (711-720 of 781) with videos related to

Sort By:
Pageof 79
Bioorganic & Medicinal Chemistry Letters|February 18, 2006
Low molecular weight indole fragments as IMPDH inhibitorsRebekah E Beevers, George M Buckley, Natasha Davies, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 2006
Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationshipsRebekah E Beevers, George M Buckley, Natasha Davies, et al.
Trials|February 14, 2026
Optimising Prescription of Treatment In older patients with Mild hypertension at Increased risk of Serious adverse Events (OPTIMISE2): protocol for a primary care based, open-label, randomised controlled non-inferiority trialMelanie Carr, Nicola Kenealy, Ly-Mee Yu, et al.
Journal of Hypertension|May 16, 2025
Developing prediction models for electrolyte abnormalities in patients indicated for antihypertensive therapy: evidence-based treatment and monitoring recommendationsAriel Wang, Constantinos Koshiaris, Lucinda Archer, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Quinazolinethiones and quinazolinediones, novel inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-activity relationshipsGeorge M Buckley, Natasha Davies, Hazel J Dyke, et al.
The Lancet. Healthy Longevity|August 2, 2024
Effect of antihypertensive deprescribing on hospitalisation and mortality: long-term follow-up of the OPTiMISE randomised controlled trialJames P Sheppard, Eleanor Temple, Ariel Wang, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 5, 2010
Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registryCyril William Helm, Scott D Richard, Jianmin Pan, et al.
BMJ Open|October 6, 2018
OPtimising Treatment for MIld Systolic hypertension in the Elderly (OPTiMISE): protocol for a randomised controlled non-inferiority trialJames P Sheppard, Jenni Burt, Mark Lown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)Annie M Young, Andrea Marshall, Jenny Thirlwall, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 11, 2025
Assessing the association between COVID-19 vaccination and thrombotic thrombocytopenia syndrome (ATTEST Study): Analyses of English data, 2020-2022José M Ordóñez-Mena, Xinchun Gu, Mark Joy, et al.
Pageof 79